Aims/hypothesis For beta cells, contact with TNF-α triggers signalling cascades that converge on pathways important for cell survival and inflammation, specifically nuclear factor κB (NF-κB), c-Jun N-terminal kinase (JNK) and p38 mitogenactivated protein kinase pathways. Here, we investigated the function of baculoviral inhibitors of apoptosis repeat containing (BIRC) proteins in regulating TNF signalling cascades. Methods TNF regulation of Birc genes was studied by mRNA expression and promoter analysis. Birc gene control of cell signalling was studied in beta cell lines, and in islets from Birc2 −/− and Birc3 −/− mice, and from Birc3 −/− Birc2Δ beta cell mice that selectively lack Birc2 and Birc3 (double knockout [DKO]). Islet function was tested by intraperitoneal glucose tolerance test and transplantation.
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Birc2Δ beta cell mice that selectively lack Birc2 and Birc3 eGFP Enhanced green fluorescent protein eGFP-Birc3 pIRES2-eGFP-Birc3 IAP Inhibitors of apoptosis IκBα Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha JNK c-Jun N-terminal kinase NF-κB Nuclear factor of kappa light polypeptide gene enhancer in B cells NIK NF-κB-inducing kinase p38 p38 mitogen-activated protein kinases Introduction TNF-α is a pleiotropic cytokine that is involved in the pathogenesis of autoimmune type 1 diabetes and influences cell proliferation, inflammation and cell death. TNF-α mediates its actions through two distinct receptors, TNF receptor (TNFR) 1/p55 and TNFR2/p75, both of which are expressed on virtually all cell types [1] . TNFR1 is predominantly responsible for TNF signalling in most cell types [1] , mediated by the sequential formation of two complexes upon TNFR1 ligation [2] . Complex I forms with the recruitment of TNFR1-associated death domain protein, which subsequently recruits TNFRassociated factor (TRAF) 2, TRAF5 and receptor-interacting protein kinase 1 (RIPK1) [2] . Within complex I, RIPK1 is essential for activating the nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-κB) pathway [3] , while TRAF2 is required for activation of the c-Jun N-terminal kinase (JNK) pathway [4] . These signalling cascades are imperative for the control of genes involved in immune response, inflammation and cell survival [1] . In addition, a secondary complex, spatially and temporally distinct from complex I, comprises Fas-associated death domain protein and caspase 8, which triggers a pro-apoptotic cascade [2] . Normally, TNF-α-stimulated cells are protected from the pro-apoptotic force of complex II by the expression of NF-κB-induced genes, including A20 (also known as Tnfaip3) and Cflip (also known as Cflar), both of which are regulated via complex I. A20 and Cflip prevent activation of caspase-8, possibly at the level of complex II [5, 6] . Thus, TNF-α triggers a co-ordinated and complex cellular program regulating cell proliferation, inflammation and cell death. The contribution of TNF-α to type 1 diabetes pathogenesis is multifaceted. A characteristic feature of diabetes is the infiltration of the pancreatic islets with T cells, with TNFRI-null islets being protected from destruction by T lymphocytes [7] . TNF-α is an early cytokine detected within the immune infiltrate surrounding islets [8] . In the context of type 1 diabetes, TNF-α exerts detrimental effects, including heightened expression of inflammatory genes in pancreatic beta cells [9] , the impairment of insulin secretion [10] and the triggering of beta cell apoptosis [5] . TNF-α's ability to induce and perpetuate diabetes has been clearly demonstrated in 3-week-old NOD mice, which upon administration of exogenous TNF-α had accelerated onset of diabetes and increased disease frequency [11] . In contrast, diabetes progression can be ameliorated by anti-TNF-α monoclonal antibody treatment [11] . Despite the importance of TNF-α in the pathogenesis of type 1 diabetes, the exact molecular machinery governing the TNF signalling cascade in islets and pancreatic beta cells remains poorly understood. An improved understanding of TNF signalling could lead to novel diagnostics or therapies for patients with type 1 diabetes.
Inhibitors of apoptosis (IAP) or baculoviral IAP repeat containing proteins (BIRC) are implicated in the regulation of downstream TNF signalling networks [12] . A total of eight BIRC proteins has been identified, namely: neuronal AIP (BIRC1), cellular IAP1 (BIRC2), cellular IAP2 (BIRC3), X-linked inhibitor of apoptosis protein (XIAP/BIRC4), survivin (TIAP/BIRC5), baculoviral IAP repeat-containing ubiquitinconjugating enzyme (BRUCE/Apollon/BIRC6), Melanoma-IAP (ML-IAP/Livin/kidney-IAP/BIRC7) and ILP-2 (Testis Specific-IAP)/BIRC8). A key cellular function of BIRC proteins is the regulation of apoptosis [12] . Indeed, XIAP can prevent apoptosis in a number of cell types, including islets [13] [14] [15] [16] by preventing direct IAP binding protein with low pI (DIABLO)-mediated cleavage of caspase 9 [17] . While BIRC proteins were thought to primarily act as regulators of apoptosis, this function has not been established for all its members; it is now recognised that BIRC proteins are also involved in the regulation of diverse cellular functions, including the regulation of signalling and inflammation [12] . Further to this, BIRC2 and BIRC3, together with TRAF2, have been identified as key components of the TNF signalling pathway that are necessary for TNF-mediated NF-κB activation [18] . With reference to beta cells, some studies have shown that beta cells express Birc3, and that Birc3 expression is regulated by the TNF-α-mediated NF-κB pathway [5, 19] ; however, its binding partner, Birc2, has not been examined. This suggested to us that in beta cells, BIRC3 may participate in a TNF signalling feedback loop, an idea that has not been tested to date. Here we examined the requirements for BIRC3 and BIRC2 in TNF signalling in beta cells.
Methods
Mouse strains BALB/c and C57BL/6 mice were from Australian BioResource (Mossvale, NSW, Australia). Birc2 loxP/lox-P were crossed with RIP-Cre mice (Cre driven by the rat insulin promoter) (Jax Mice, Bar Harbour, ME, USA) to generate beta cell-specific double knockout Birc3 −/− Birc2Δ beta cell mice that selectively lack Birc2 and Birc3 (double knockout [DKO] ). Procedures complied with the Australian Code of Practice for Care and Use of Animals for Scientific Purposes.
Cytokines Mouse islets were isolated as described [20] . Either 70-100 islets or 1×10 6 MIN6 beta cells [21] were stimulated with 200 U/ml of TNF-α for 4 h (RNA analysis) and 8 h (promoter analysis) (R&D Systems, Minneapolis, MN, USA). β-TC 3 cells were used for some transfection studies [22] . In some cases, cells were pretreated for 1 h with 1 μmol/l actinomycin D, 50 μmol/l SP600125, 1 μmol/l MG-132 and 50 μmol/l pyrrolidine dithiocarbamate (PDTC) (all from Sigma-Aldrich, St Louis, MO, USA), and with 20 μmol/l SB203580 (Cell Signalling Technology, Beverly, MA, USA), prior to cytokine stimulation. Western blotting was performed using standard protocols with IκBα antibody (9242L), phospho-c-Jun (Ser73, 9164S) (Cell Signalling Technology), β-actin (Clone AC-15; A5441; SigmaAldrich) and horseradish peroxidase-conjugated antibodies (Pierce, Rockford, IL, USA), and chemiluminescence (GE Healthcare, Uppsala, Sweden).
Quantitative RT-PCR Total RNA and cDNA were generated from beta cell lines and mouse islets using standard techniques previously described by this research group [5] . Relative gene expression is the ratio to the housekeeping gene, Cyclophilin A (Ppia); fold-changes were analysed using the 2 À$$C t method. Primers used for PCR are provided in electronic supplementary material (ESM) Table 1 .
Cloning of Birc3 and promoter The Birc3 coding region was cloned from cytokine-stimulated mouse islets, using the primers shown in ESM Table 2 , with a PCR system (Expand High Fidelity PCR; Roche, Indianapolis, IN, USA), and subcloned into a pIRES2-eGFP vector (Clontech Laboratories, Mountain View, CA, USA). Putative transcription factor binding sites in the Birc3 proximal promoter were identified using PROMO3.0 [23] . The mouse Birc3 5′ untranslated region was amplified from genomic DNA using the primers shown in ESM Table 3 with KOD Hot Start DNA Polymerase (Merck, Darmstadt, Germany) and subcloned into a pGL3 basic vector (Promega, Sydney, NSW, Australia).
Transient transfections Transfection of MIN6 and β-TC 3 cells was performed using techniques and expression plasmids encoding NF-κB.Luc (Promega), RelA/p65, A20.Luc, and plasmid containing beta galactosidase under the control of the Rous Sarcoma virus (pRSV-β-galactosidase) as previously described by us [5] . Luciferase values (Luciferase Assay System; Promega) were normalised to β-galactosidase activity (j) Induction by RelA/p65 of endogenous Birc genes mRNA, as indicated, in β-TC 3 cells. Birc1a, also known as Naip1; Birc1b, also known as Naip2; Birc1e, also known as Naip5; Birc1f, also known as Naip6; Birc4, also known as Xiap. (Galacto-Star; Applied Biosystems, Bedford, MA, USA) for relative luciferase activity.
Adenovirus transduction MIN6 cells (1×10 6 ) were infected for 1.5 h with recombinant adenovirus expressing GFP (rAd.GFP) or rAd.IκBα [24] at a multiplicity of infection of 100:1 in serum-free medium before adding FCS-enriched medium to achieve a 10% (vol./vol.) FCS concentration. Cells were incubated overnight and the medium was replaced prior to stimulation with TNF-α for 4 h.
In vivo studies Intraperitoneal glucose tolerance tests were performed on 12-week-old male mice administered 2 g/kg glucose following a 16 h fast. For islet transplantation, islets from donor (H-2 b ) mice were transplanted into recipient mice (H-2 k ) that had been rendered diabetic with 200 mg/kg streptozotocin (Sigma-Aldrich) as previously described [25] .
Statistics Statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA).
Results
Birc3 is an early immediate-response gene regulated by de novo transcription In the steady state, Birc3 was highly expressed (Fig. 1a ) and was selectively increased by TNF-α in primary islets (p ≤ 0.0001) (Fig. 1b ) and MIN6 cells (Fig. 1c, d ). Once induced, high levels of Birc3 mRNA were maintained in primary islets (p≤0.01 and p≤0.0001) (Fig. 1e ) and MIN6 cells (p≤0.01 and p≤0.001) (Fig. 1f) .
To determine the mechanism of Birc3 induction, primary islets and MIN6 cells were pretreated with the transcription inhibitor, actinomycin D, prior to TNF-α stimulation. Pretreatment with an optimal dose of actinomycin D (1 μmol/l) resulted in >70% suppression of TNF-α-induced Birc3 expression in islets (p≤0.0001) (Fig. 2a ) and MIN6 cells (p ≤ 0.001) (Fig. 2b) . Thus Birc3 is an inflammationregulated, early immediate-response gene regulated via de novo gene transcription.
NF-κB controls TNF-induced Birc3 expression
The 5′ untranslated region of the Birc3 proximal promoter contained three putative consensus NF-κB binding sites and a TATAlike box with the sequence TTTAAA' (Fig. 2c) . Potential putative activator protein 1, signal transducers and activators of transcription 1 and protein 53 (p53) binding sites were also identified. This region was cloned to generate the Birc3 reporter, which showed an approximately twofold increase upon TNF-α stimulation (p≤0.01) (Fig. 2d) . These results indicate that the Birc3 proximal promoter contains cytokine responsive elements that direct Birc3 gene expression.
To determine the molecular mechanisms driving Birc3 transcription, MIN6 cells were left untreated, or were pretreated with SP600125, SB203580 or PDTC to selectively target the JNK, p38 mitogen-activated protein kinases (p38) or NF-κB pathways respectively, prior to TNF-α stimulation. Birc3 mRNA levels were measured by quantitative RT-PCR. Neither SB203580 (Fig. 2e) nor SP600125 (Fig. 2f) , but only PDTC pre-treatment inhibited TNF-α-induced Birc3 expression, e.g. by ∼90% for MIN6 cells (p≤0.05) (Fig. 2g) and ∼75% for islets (p≤0.05) (Fig. 2h) . These data show that NF-κB is necessary for TNF-α-induced Birc3 expression.
NF-κB is sufficient to drive de novo Birc3 expression When MIN6 cells were co-transfected with Birc3 reporter and a RelA/ p65 expression vector, Birc3 reporter activity was increased by twofold (p≤0.001) (Fig. 2i) . To determine whether RelA/p65 was sufficient to drive endogenous Birc3 gene expression, β- Data represent mean ± SEM from four independent experiments. Statistical comparisons were made by single unpaired t test between two groups or by ANOVA with pairwise multiple comparisons made using an unpaired t test. *p≤0.05, **p≤0.01, ***p≤0.001 and ****p≤ 0.0001 p≤0.05) (Fig. 2j) . Moreover, overabundance of IκBα in MIN6 cells (Fig. 2k ) resulted in a 77% suppression of TNF-α-induced Birc3 expression (p≤0.01) (Fig. 2l) . Thus, NF-κB is necessary and sufficient to drive de novo transcription of Birc3 mRNA.
Increased Birc3 regulates NF-κB signalling Our results imply a model whereby TNF-α activates NF-κB, which subsequently induces increased Birc3 expression. To elucidate the function of increased Birc3 in pancreatic beta cells, MIN6 cells were transfected with the pIRES2-eGFP control vector or 0.3 to 0.6 μg pIRES2-eGFP-Birc3 (eGFP-Birc3). eGFP-Birc3-transfected MIN6 cells expressed Birc3 in a range similar to TNF-α-stimulated MIN6 cells (i.e. 12-fold, p≤0.001) (Fig. 3a) . Subsequently, MIN6 cells were transfected with a luciferase reporter containing two tandem NF-κB responsive elements (NF-κB.Luc), plus either 0.1 to 0.6 μg eGFP-Birc3, or 0.6 μg control vector. In MIN6 cells, eGFP-Birc3-expressing cells showed a dose-dependent increase in NF-κB reporter activity (Fig. 3b) , while a combination of TNF-α stimulation and 0.6 μg eGFP-Birc3 showed a further increase of NF-κB reporter activity, from 3.4-fold (p≤0.05) with TNF-α alone to sevenfold with eGFP-Birc3 (p≤0.01).
To elucidate how Birc3 modulates a native NF-κB promoter, the effect of Birc3 activity on the NF-κB-driven A20 reporter [5] was examined. β-TC 3 cells were transfected with 2 μg A20.Luc and either 0.25 μg pIRES2-eGFP control vector or eGFP-Birc3. A20 reporter activity increased from sevenfold (p≤0.001) for TNF-α alone to 9.5-fold for TNF-α and eGFP-Birc3 (Fig. 3c ). These data demonstrate that increased Birc3 expression is sufficient to drive NF-κB activity and enhance TNF-α-induced NF-κB signalling.
A redundant role for Birc3 in NF-κB signalling The effect of Birc3 loss-of-function on beta cell TNF-α-mediated NF-κB signalling was examined in Birc3 −/− mice (Fig. 4a) .
Birc3 is not necessary for beta cell function as indicated by the normal glucose tolerance of Birc3 −/− mice (Fig. 4b) .
We analysed TNF-α-induced NF-κB signalling in wild-type or Birc3 −/− islets via western blot analysis of IκBα levels [26] . Compared with wild-type islets, TNF-α-stimulated 
Birc3
−/− islets showed delayed IκBα degradation, but a normal return to baseline levels at 60 min (Fig. 4c) . Analysis of NF-κB-regulated and TNF-α-induced genes in Birc3 −/− islets revealed an abnormal expression pattern. While normal A20 induction (Fig. 4d) was observed, expression of Ccl2 (p≤0.01) (Fig. 4e) and Cxcl10 (p≤0.01) (Fig. 4g ) was reduced, with Icam1 levels being modestly increased (p≤0.01) (Fig. 4f) . These data indicate that BIRC3 is necessary to fine-tune cellular responses to TNF-α.
Birc2 provides negative control of TNF pathways in beta cells BIRC2 can compensate for BIRC3 [3, 27] , therefore we examined NF-κB signalling in single Birc2 −/− islets (Fig. 5a ). Birc2 −/− mice had normal glucose homeostasis (Fig. 5b) . Regarding NF-κB signalling, Birc2 −/− islets had delayed kinetics of TNF-α-stimulated IκBα degradation (Fig. 5c) . Noticeably, in the absence of a pro-inflammatory stimulus, Birc2 −/− islets expressed high levels of Ccl2 (ninefold greater, p≤0.01) (Fig. 5e ) and Cxcl10 (sevenfold greater, p ≤ 0.05) (Fig. 5g ) compared with wild-type islets. Furthermore, while TNF-α-stimulated Birc2 −/− islets expressed normal induced levels of A20 (Fig. 5d) , induction of Ccl2 (threefold, p≤ 0.001) and Icam1 (threefold, p ≤ 0.0001) mRNA was significantly higher than for wild-type islets (Fig. 5e, f) . These findings suggest that Birc2 functions as a negative control factor, dampening expression of TNF target genes in islet cells.
Dysregulated gene expression in the absence of Birc2 and Birc3
As BIRC2 and BIRC3 can compensate for each other to allow NF-κB signalling [3, 27] , we generated DKO mice. DKO islets exhibited loss of BIRC2 and BIRC3 (Fig. 6a, b ), but normal glucose homeostasis, indicating that these two proteins are dispensable for physiological beta cell function (Fig. 6c) . Analysis of TNF-α-induced IκBα degradation revealed that NF-κB signalling kinetics were significantly delayed in the absence of BIRC2 and BIRC3 (Fig. 6d) . Moreover, DKO islets showed significant disturbances in the regulation of TNF target genes, expressing significantly higher stimulus-independent levels of A20 (fourfold, p≤0.0001), Ccl2 (eightfold, p≤0.001), Icam1 and Cxcl10 (17-fold, p≤0.05) compared with resting wildtype islets (Fig. 6e-h) . Analysis of TNF-α-induced responses showed hyperinduction of A20 (threefold, p≤ 0.0001), Ccl2 (fourfold, p≤0.0001) and Icam1 (18-fold, p≤0.001), but not of Cxcl10 mRNA compared with wildtype islets (Fig. 6e-h) . Therefore, Birc2 
Birc2 and Birc3 fine-tune inflammatory gene expression in islet cells
We examined the relative contribution of BIRC2 and BIRC3 to the phenotypes observed for DKO islets. We found that in the absence of a TNF-stimulus, A20 (p≤0.0001) (Fig. 7a) and Icam1 (p≤0.0001) (Fig. 7c) (Fig. 7b) . Like Ccl2, control of Cxcl10 expression appears to be more strongly dependent on the presence of BIRC2 (p≤0.05 and p≤0.05) (Fig. 7d) .
BIRC proteins regulate gene transcription through JNK When DKO islets were treated with actinomycin D, the stimulusindependent expression of A20 (13-fold, p≤0.0001) and Cxcl10 (tenfold, p≤0.01), but not of Ccl2 or Icam1, was suppressed ( Fig. 7e-h ), indicating that basal A20 and Cxcl10 mRNA levels are regulated by active transcription in DKO islets. We hypothesised that the increased stimulus-independent transcription rates of A20 and Cxcl10 in DKO islets might be due to loss of control of the normal regulatory paths that control TNF-α-induced gene expression. We first sought to identify the possible pathways involved in normal TNF-α-induced gene expression. To do this, MIN6 cells were left untreated, or were pretreated with PDTC, SP600125 or SB203580 to inhibit NF-κB, JNK or p38 respectively, prior to TNF-α stimulation for 4 h. Our findings show that, in MIN6 cells, TNF-α-stimulated A20 was regulated by NF-κB, but not by the JNK or p38 pathways (Fig. 8a) , whereas TNF-α-induced Ccl2, Icam1 and Cxcl10 expression was regulated by the NF-κB and the JNK pathways (Fig. 8b-d) .
We next tested the idea that the increased stimulusindependent gene expression in DKO islets might be due to hyperactivation of those same pathways involved in the regulation of normal TNF-α-induced gene expression. To test this, DKO islets were treated with inhibitors and gene expression was analysed by quantitative RT-PCR. Notably, the stimulus-independent expression of Ccl2, Icam1 and Cxcl10 was sensitive to SP600125, but not to SB203580 or PDTC treatment (Fig. 8e-h ). Moreover, examination of JNK activation by analysis of c-Jun phosphorylation showed hyperphosphorylation of c-Jun in DKO islets compared with wild-type islets (Fig. 8i) . These findings indicate that loss of Birc2 and Birc3 dysregulates fine control over the JNK pathway, such that beta cells are hypersensitive to the triggering of JNK signalling, resulting in the loss of fine control over gene transcription.
Proteosome inhibition mimics BIRC2 and BIRC3 deficiency BIRC proteins function as ubiquitin modifying enzymes that target proteins for proteosomal degradation [12] . We tested the idea that, in the absence of BIRC proteins, the accumulation of signalling components normally targeted for degradation, perhaps regulatory kinases, could trigger activation of signalling pathways without appropriate external inputs. To do this, we treated MIN6 cells with the proteosome inhibitor, MG-132, to examine whether loss of proteosome activity could replicate the DKO islet phenotype. Compared with control MIN6 cells, MG-132-treated cells exhibited increased expression of Ccl2 (50%, p≤0.05), Icam1 (50%, p≤0.001) and Cxcl10 (80%, p ≤ 0.05), but not of A20 (Fig. 9a-d) .
Moreover, based on analysis of c-Jun phosphorylation, MG-132-treated MIN6 cells also showed increased JNK pathway activation (Fig. 9e) . Thus blockade of the proteosome resulted in dysregulated JNK pathway activation in a stimulus-independent manner, with hyperexpression of Ccl2, Icam1 and Cxcl10 inflammatory genes.
DKO islets have impaired function after transplantation JNK is acutely activated in islet cells during the process of islet isolation [28] and antagonisation of JNK signalling is beneficial for islet survival after isolation [29] . Therefore, we predicted that DKO islets would fair worse in vivo following transplantation. To test this idea, wild-type or DKO islets were transplanted into diabetic allogeneic recipients. Analysis of blood glucose levels showed that wild-type and DKO islets provided good metabolic control immediately after transplantation (Fig. 10) . As early graft function can be affected by loss of islet mass due to cell death [30, 31] , this suggests that DKO islets were not hypersensitive to death stimuli. However, by post-operative day 6, the function of DKO islets began to deteriorate, a process that worsened with time. In contrast, wild-type islets showed good metabolic control until at least post-operative day 18. The earlier 
Discussion
Our studies present novel insights into the molecular control of TNF signalling in primary pancreatic beta cells and the role of BIRC proteins in this process. Surprisingly, both single Birc2 −/− and DKO islets, as well as MIN6 cells treated with proteosome inhibitors, exhibited dysregulated expression of select TNF target genes. The augmented stimulus-independent expression of Ccl2, Cxcl10 and Icam1 mRNA observed for DKO islets was substantially reduced by antagonising JNK signalling. Also, DKO islets showed stimulus-independent hyperphosphorylation of c-Jun. We were also able to demonstrate a role for the JNK pathway in the normal de novo regulation of these same genes in islets and beta cells. These data could indicate that BIRC2 and BIRC3 negatively regulate the JNK pathway and subsequent JNK/activator protein-1-regulated gene expression in islet cells. Interestingly, for B lymphocytes, loss of BIRC2 also leads to prolonged TNF-mediated JNK signalling [32] . BIRC2 and BIRC3 are recruited to the TNFR1 complex via interaction with TRAF2 [18, 33] . TRAF2 is necessary for TNF-α-mediated JNK signalling, but is redundant in the NF-κB or p38 pathways [4, 34, 35] . BIRC2 modulates the duration of TNF-α-induced JNK signalling by targeting TRAF2 and the mitogen-activated protein kinase kinase kinase protein, apoptosis signal-regulating kinase 1 (ASK1), for proteosomal degradation [32, 36] . Our data indicate that this pathway may operate in beta cells. Indeed, treatment of MIN6 cells with the proteosome inhibitor, MG-132, phenocopied DKO islets, lending support to this concept. Hence, one possibility is that, in the absence of BIRC2 and/or BIRC3, TRAF2 and ASK1 accumulate, subsequently triggering hyperactivation of c-Jun, with dysregulated expression of downstream target genes. Hyperactivation of c-Jun might also affect the duration of signalling, contributing to the enhanced gene expression observed for DKO islets following TNF-ligation.
The stimulus-independent expression of Cxcl10 and A20 observed in DKO islets showed different sensitivities to JNK inhibition; hyperexpression of A20 was not sensitive to JNK inhibition. In islets, A20 is an NF-κB-regulated gene [5] that forms a feedback loop to modulate NF-κB activation [20, 37] and control inflammation [38] . Some data show that BIRC antagonists promote degradation of BIRC proteins, which can subsequently trigger stimulus-independent NF-κB signalling. This may be mediated by increased availability of RIPK1, allowing RIPK1-TNFR1 interactions to trigger NF-κB activation [39] , subsequently driving expression of NF-κB target genes [40] . Another possibility is regulation of the non-canonical NF-κB component, v-rel reticuloendotheliosis viral oncogene homolog B (RelB). Indeed, Relb −/− fibroblasts exhibit increased NF-κB activity with stimulusindependent expression of NF-κB target genes [41] . Moreover, the non-canonical pathway is regulated at the level of NF-κB-inducing kinase (NIK) [42] . Birc2 −/− mouse embryonic fibroblasts cells (MEFs) and Birc2 −/− Birc3 −/− cancer cells accumulate high NIK levels, and NIK in turn phosphorylates IκB kinase (IKK)α, inducing activation of the non-canonical NF-κB pathway [39, 40] . Hence BIRC2 and BIRC3 provide negative regulatory control over noncanonical NF-κB signalling.
With regard to NF-κB, DKO islets, interestingly, exhibit altered kinetics of IκBα degradation, which presumably reflects a necessary role for BIRC proteins in controlling the speed of NF-κB signalling in beta cells. NF-κB activation is sensitive to proteosome inhibition [43, 44] , and BIRC proteins, via their Really Interesting New Gene (RING) domains, can target substrates for proteosomal degradation through ubiquitin editing [3] . One BIRC substrate is RIPK1, which recruits the transforming growth factor (TGF)-beta activated kinase 1 (TAK1)-TGF-beta activated kinase 1/mitogen-activated protein kinase kinase kinase 7 (MAP3K7) binding protein 2 (TAB2)-TAB3 and IKKα-IKKβ-NF-κB essential modulator (NEMO) complexes, triggering TAK1-dependent phosphorylation of IKKβ [45] . The activated NF-κB signalosome [46] subsequently phosphorylates IκBα, initiating the necessary steps for NF-κB translocation [47] . Thus, by controlling the availability of RIPK1 through ubiquitin editing [39] , BIRC proteins have the capacity to fine-tune the speed of NF-κB signalling.
Our data provide new insights into the mechanisms by which BIRC proteins control TNF signalling. TNF-α stimulation induces NF-κB activation, which drives early immediate expression of Birc3 in beta cells. The increased levels of BIRC3 may be required to fine-tune TNF-induced inflammatory signalling for full expression of TNF-α-induced genes like Ccl2 and Cxcl10, while suppressing others, including Icam1. Thus, increased BIRC3, in combination with BIRC2, acts simultaneously as a positive factor for NF-κB signalling, but also as a molecular brake that provides modulatory control over the JNK signalling axis. BIRC proteins prevent activation of this pathway in the absence of an overt extracellular signal normally provided by TNF. Thus under inflammatory conditions, pancreatic islets rapidly induce Birc3 to fine-tune NF-κB and JNK signalling pathways to ensure beta cell transcriptional responses are appropriately matched to extracellular inputs. Maintaining a balanced response may be critical for beta cell function under conditions of cellular stress. Thus, for example, beta cell failure in the context of type 2 diabetes is associated with exacerbated CXCL10 expression [48] , while activation of the JNK pathway impairs islet survival and function [49, 50] . Moreover, as shown here in the context of islet transplantation, the absence of BIRC proteins impairs islet grafts, resulting in a more rapid loss of glucose homeostasis. 
